Verve Therapeutics
Why Heart Disease
Verve Therapeutics was created with a singular focus to protect the world from heart disease
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide.
Verve brings together two of the biggest breakthroughs in 21st century biomedicine — human genetic analysis and gene editing — to realize a new future, one of longevity and vitality for tens of millions of people worldwide at risk of coronary artery disease.
Verve Team
Verve has been purpose-built for the task ahead, with a founding team of world-leading experts in cardiovascular medicine and patient care, cardiovascular genetics, gene editing delivery technology and safety, drug development, and company-building.
Sekar Kathiresan, M.D.
Co-Founder and Incoming Chief Executive Officer
Kiran Musunuru, M.D., Ph.D., MPH
Co-Founder and Chief Scientific Advisor
J. Keith Joung, M.D., Ph.D.
Anthony Philippakis, M.D., Ph.D.
Co-Founder and Board Member
Burt Adelman, M.D.
Co-Founder and Chairman of the Board
Barry Ticho, M.D., Ph.D.
Issi Rozen, MBA
Co-Founder and Strategic Advisor
Andrew Ashe, J.D.
President and Chief Operating Officer
David Neafus, CPA
Interim Chief Financial Officer
Andrew Bellinger, M.D., Ph.D.
Chief Medical Advisor
Robert Millman, J.D.
Intellectual Property and Business Advisor
Kallanthottathil G. Rajeev, Ph.D.
Vice President, CMC
Alexandra Chadwick, Ph.D.
Associate Director, Preclinical Research and Development
Robin Eisner
Administrative and Operations Manager
Thomas Colace, Ph.D.
Associate Principal Scientist
Jamie DeNizio, Ph.D.
Wenjun Li
Michael Amaonye
Krishna Yeshwant, M.D., MBA
John Evans, MBA
Jessica Alston, Ph.D.
Board Observer
Boris Nikolic, M.D.
Eugene Braunwald, M.D.
Penny M. Heaton, M.D.
Daniel J. Rader, M.D.
Collaborations and Licensing
Verve has established foundational collaborations with industry leaders in gene editing and delivery technologies, including Beam Therapeutics and Verily. The company also has in-licensed technology from the Broad Institute and Harvard University.
Verve is supported by a top-tier syndicate of investors who share our vision for tackling the world's most urgent health challenge.
Verve Therapeutics, Inc., all rights reserved